ADVITOS, an EIT Digital-supported company, is the world's first multi-organ support system for lungs, liver, kidney, and acid-base balance.
Based on the principle of albumin dialysis, ADVITOS' ADVOS system helps eliminate CO2 and toxins in the body and corrects metabolic and respiratory acidosis. It addresses the critical ways organ dysfunction can negatively affect other organs and frequently lead to death for patients in intensive care.
ADVITOS achieves major milestone through EIT Digital
EIT Digital began promoting ADVITOS in 2019, supporting them all the way to CEO and co-founder Catherine Schreiber's first place win for the EIT's Women Leadership Award in 2022.
The Munich-based company was especially supported by the EIT Digital Accelerator, through which it completed a EUR 20 million financing round. The round was led by Crédit Mutuel Equity via its two subsidiaries, Crédit Mutuel Equity Germany and Crédit Mutuel Innovation. ADVITOS also received funding from the European Union’s European Innovation Council (EIC) Fund as part of the EIC Accelerator Pilot blended finance programme. The EIT Digital Accelerator helped ADVITOS through the process with dedicated coaching and targeted introductions to a selected pool of investors interested in their space, size and geography.
This financing round is a major step in the further development of ADVITOS. It will enable us to grow much faster and seize the enormous market potential this unique and certified therapy has, not only in Europe, but globally.
Dr. Bernhard Kreymann, Founder and then-CEO of ADVITOS
We have been lucky in taking advantage of the fundraising programme offered by EIT Digital, and valued the expertise, persistence, and outreach that the EIT Digital Accelerator team has offered to us. Providing this kind of highly competent hands-on fundraising support is a strongly needed and highly effective measure to secure and enable scaling of European deep tech innovations.
Catherine Schreiber, co-founder and current CEO of ADVITOS
ADVOS - treating multiple organ failure
ADVITOS developed the ADVOS multi device (ADVanced Organ Support) to provide an integrated 4-in-1 multi-organ support therapy that enables simultaneous support of all three main detoxification organs – liver, lungs, and kidney – and corrects blood acid-base imbalances. Pilot trials in critically ill patients have shown that this therapy increased survival in severe organ failure from 20% up to 50%.
Multi-organ failure causes the deaths of approximately half a million intensive care patients in Western Europe and the USA every year. This is about 60% of all deaths in intensive care units. Due to the COVID-19 pandemic, this number has increased to around 750 000 patients in the past year.
Conventional extracorporeal procedures such as mechanical ventilation, ECMO (extracorporeal membrane oxygenation), dialysis, and liver-assist therapy only support the function of one or two organs. By treating all three organs simultaneously, and not consecutively as existing solutions do, ADVOS offers a holistic approach that gives patients a much better chance of recovery.
The ADVOS therapy is CE marked, recognised by international experts, and is already in use in the intensive care units in hospitals throughout Germany, including a number of leading university hospitals.
The company has now received numerous awards, including the 2020 Innovation Award Bavaria, and is listed in the Deloitte Technology Fast 50 Awards 2019.